An Exemestane Derivative, Oxymestane-D1, as a New Multi-Target Steroidal Aromatase Inhibitor for Estrogen Receptor-Positive (ER(+)) Breast Cancer: Effects on Sensitive and Resistant Cell Lines

Around 70–85% of all breast cancer (BC) cases are estrogen receptor-positive (ER(+)). The third generation of aromatase inhibitors (AIs) is the first-line treatment option for these tumors. Despite their therapeutic success, they induce several side effects and resistance, which limits their efficac...

Descripción completa

Detalles Bibliográficos
Autores principales: Amaral, Cristina, Correia-da-Silva, Georgina, Almeida, Cristina Ferreira, Valente, Maria João, Varela, Carla, Tavares-da-Silva, Elisiário, Vinggaard, Anne Marie, Teixeira, Natércia, Roleira, Fernanda M. F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9865664/
https://www.ncbi.nlm.nih.gov/pubmed/36677847
http://dx.doi.org/10.3390/molecules28020789

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9865664/
https://www.ncbi.nlm.nih.gov/pubmed/36677847
http://dx.doi.org/10.3390/molecules28020789

Ejemplares similares